0001104659-23-128788.txt : 20231222 0001104659-23-128788.hdr.sgml : 20231222 20231222160523 ACCESSION NUMBER: 0001104659-23-128788 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231220 FILED AS OF DATE: 20231222 DATE AS OF CHANGE: 20231222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jin David CENTRAL INDEX KEY: 0001930732 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35366 FILM NUMBER: 231509771 MAIL ADDRESS: STREET 1: C/O AVENUE THERAPEUTICS, INC. STREET 2: 1140 AVENUE OF THE AMERICAS, FLOOR 9 CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fortress Biotech, Inc. CENTRAL INDEX KEY: 0001429260 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 205157386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 FORMER COMPANY: FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC DATE OF NAME CHANGE: 20080310 4 1 tm2333573-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-12-20 0 0001429260 Fortress Biotech, Inc. FBIO 0001930732 Jin David C/O FORTRESS BIOTECH, INC. 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 0 1 0 0 Chief Financial Officer 0 COMMON STOCK, PAR VALUE $0.001 2023-12-20 4 A 0 140000 0.00 A 235916 D Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. Represents an award of 140,000 restricted stock units which will vest in 16 equal quarterly installments after the grant date, December 20, 2023. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Corporate Transaction (as defined in the Fortress Biotech, Inc. 2013 Stock Incentive Plan); the amount will be distributed in the form of the Issuer's common stock. Total holdings include 230,000 shares underlying deferred restricted stock units. /s/ David Jin 2023-12-22